With potential multibillion-dollar buyout or drug approval, Cytokinetics' 1st employee close to taking company to finish line
Novartis AG is in advanced talks to buy Cytokinetics, the Wall Street Journal reported Monday, just weeks after Cytokinetics disclosed strong late-stage clinical trial results for a heart failure drug.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Cardiology | Clinical Trials | Health Management | Heart | Heart Failure | Pharmaceuticals